5 Patients Randomized
Paradigm Clinical Research enrolled 5 patients into a Phase III vTv Therapeutics T1D study across two site locations, with a contractual randomization commitment at each engagement. The campaign performed well enough that Paradigm renewed for a third run at a new site.
Check if your study qualifies5
Patients Randomized
$12,500
Campaign Investment
$2,500
Cost Per Randomized Patient
A Phase III Requirement in a Condition With a Narrow Patient Profile
Paradigm Clinical Research was running a Phase III trial of cadisegliatin as adjunctive therapy to insulin in participants with Type 1 Diabetes Mellitus — a vTv Therapeutics-sponsored study with specific eligibility requirements tied to diagnosis history and current treatment protocol.
The addressable patient pool for a T1D study on insulin is smaller than many Phase III indications. The site needed a recruitment partner who had evaluated the feasibility math before committing — not one who would invoice for activity while the enrollment gap widened.
Paradigm needed referrals pre-screened against T1D-specific criteria and a contractual commitment that matched the site's accountability to the sponsor.
Feasibility Confirmed. Commitment Extended. Campaign Deployed.
Clinical Enroll evaluated Paradigm's T1D protocol for feasibility before any campaign work began — modeling the addressable patient population, eligibility criteria complexity, and per-site enrollment targets. The commitment was confirmed supportable and formalized in contract. An IRB-compliant campaign was built and deployed across condition-targeted digital channels, with a pre-screening questionnaire aligned to the study's inclusion and exclusion criteria. Patients who did not meet the T1D-specific threshold were not referred.
5 Randomized Patients. Renewed Twice.
The campaign delivered 5 randomized patients across two Paradigm site locations against a combined $12,500 investment — a cost per randomized patient of $2,500.
The most direct signal of campaign performance: Paradigm extended the engagement to a second site location after the first run, then renewed for a third run at a new site. Repeat engagements are not a standard feature of recruitment campaigns that underperform.
Per-patient site fees for Phase III studies typically range from $8,000 to $20,000 per randomized patient depending on indication and protocol complexity. At an estimated $8,000 to $20,000 per-patient site fee, 5 randomized patients represents a potential $40,000 to $100,000 in patient revenue against a $12,500 campaign investment.
POTENTIAL ROI
$12,500
Campaign investment
$8k–$20k
Per-patient site fee range
$40k–$100k
Potential patient revenue
Find out if your study qualifies for the same commitment.
Not every study is a fit. Clinical Enroll conducts a feasibility evaluation before extending a randomization commitment. If your protocol and patient population support it, you'll receive a campaign proposal with a contractual outcome guarantee — not a media budget and a projection.
All campaigns developed for IRB review and deployed in accordance with FDA guidance on clinical trial advertising.